Androgen Deprivation Therapy With or Without Docetaxel in High-Risk Biochemically Recurrent Prostate Cancer After Surgery
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy With or Without Docetaxel in High-Risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Eur Urol Oncol 2021 May 18;[EPub Ahead of Print], MJ Morris, JM Mota, K Lacuna, P Hilden, M Gleave, MA Carducci, F Saad, ED Cohn, J Filipenko, G Heller, N Shore, AJ Armstrong, HI ScherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.